Quintiles, SNUH announce clinical research partnership

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today celebrated its 10^th year anniversary in South Korea by announcing a strategic alliance with the Seoul National University Hospital (SNUH) as part of its unique Prime Site program. SNUH is Quintiles' second Prime Site in Asia, adding to six other existing sites located in the United States, Europe and Africa.

“Prime Sites are large clinical institutions that Quintiles collaborates with to enhance their infrastructure for conducting clinical trials in order to accelerate the development of new and more effective medicines”

"Prime Sites are large clinical institutions that Quintiles collaborates with to enhance their infrastructure for conducting clinical trials in order to accelerate the development of new and more effective medicines," explained Michael Klein, M.D., Vice President, Quintiles Southeast Asia and South Korea. "SNUH is an ideal partner for us for three reasons; South Korea is an increasingly important player in Asia-Pacific clinical drug development; we have a talented and engaged workforce in South Korea that has a heritage of delivering quality clinical research; and SNUH has embraced a shared vision for this model as we aim to improve human health."

Professor Yung-Jue Bang, M.D., Ph.D., Director of Clinical Trials Center, SNUH, said, "We are proud of our reputation and experience in conducting international-caliber clinical research across multiple therapeutic areas. We believe that this partnership will help us drive improved productivity and the quality of our clinical research and will place us firmly on the world map as a leading clinical institution."

Asia holds special promise for the global pharmaceutical industry as companies work to minimize time and cost to market and capitalize on innovation in the region. As an industry pioneer, Quintiles helps its customers navigate risks and seize opportunities in the New Health landscape. This alliance with SNUH reinforces that commitment and is a key step toward enabling the region to deliver on its potential in the clinical drug development industry.